Lone Star Funds takes majority stake in Lonza Chi
Context
Lone Star Funds has entered into a definitive agreement to acquire a majority stake in Lonza Group’s Capsules & Health Ingredients (CHI) division. Lonza will retain a 40% equity position in the newly independent business, ensuring industrial continuity and shared upside in the future growth of the platform. The strategic rationale for Lonza is the completion of its long-term transformation into a "pure-play" CDMO (Contract Development and Manufacturing Organization). For CHI, the transition to a standalone entity under Lone Star’s control is designed to enhance its strategic agility and provide the dedicated capital necessary to accelerate innovation in plant-based capsules and nutritional ingredients. The sale process, which began in late 2024, was advised by Bank of America and Centerview Partners. This carve-out follows several other Lonza divestitures, including its Personalized Medicines and MODA software businesses.
By taking control of Lonza Chi, Lone Star Funds continues its expansion strategy. Previously, the group had completed 2 acquisitions, including SPX Flow in 2022.
Lonza Chi, which reported an EBITDA margin of [members only] in 2024, is valued in this transaction at an EV/EBITDA multiple of 5x–12x.
-> Deep-dive in Healthcare & Pharma market trends
Target
Lonza CHI (Capsules & Health Ingredients) is a global leader in the production of hard capsules and dosage form solutions for the pharmaceutical and nutraceutical industries. The business operates across three integrated segments: Hard Empty Capsules (gelatin and plant-based), Dosage Form Solutions, and Health Ingredients (science-backed nutrition for joint health and energy). With a manufacturing footprint spanning the Americas, Europe, and Asia Pacific, CHI is recognized for its high-quality technical capabilities and established relationships with blue-chip global customers. The entity acts as a critical supply chain partner, offering end-to-end development platforms from raw ingredients to finished dosage forms, benefiting from structural growth trends in the global health and active lifestyle markets.
Ent. Value
CHF 1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
1x–3x
EV / EBITDA
5x–12x
EV / EBIT
[members only]
Historical Financials (CHF)
Other operations with Lone Star Funds
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2022 | LONE STAR FUNDS | SPX FLOW | UNITED STATES | Special Machinery |
| 07/2017 | LONE STAR FUNDS | ESMALGLASS | SPAIN | Specialty Chemicals |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2026 | REVENIO GROUP CORPORATION | VISIONIX INTERNATIONAL | FRANCE | Diagnostic Equipment |
| 04/2026 | GILEAD SCIENCES | ARCELLX | UNITED STATES | R&D Biotech |
| 03/2026 | SIPAREX | WINNCARE | FRANCE | Medical Devices |
| 03/2026 | ABBOTT LABORATORIES | EXACT SCIENCES | UNITED STATES | Diagnostic Equipment |
| 03/2026 | DEUTSCHE BETEILIGUNGS (DBAG) | HIPP TECHNOLOGY GROUP | GERMANY | Implants & Prosthetics |
| 03/2026 | RESONETICS | RESOLUTION MEDICAL | UNITED STATES | Medical Devices |
| 02/2026 | VIVO CAPITAL | DUTSCHER | FRANCE | Medical Consumables |
| 02/2026 | CIMG | DAREN TECHNOLOGY | CHINA | R&D Biotech |
| 02/2026 | IMA GROUP | PROSYS | IRELAND | Medical Devices |
| 02/2026 | NORD HOLDING | HALLMARQ VETERINARY IMAGING | UNITED KINGDOM | Diagnostic Equipment |
REFERENCES
Valuation range: EV CHF 1–10bn
Revenue range: CHF 1–10bn
EBITDA range: CHF 250–500M
EV/Revenue range: 1x - 3x
EV/EBITDA range: 5x - 12x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Lonza Chi by Lone Star Funds are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
FAQ
What transaction does this page cover?
How was the acquisition of Lonza Chi by Lone Star Funds valued, and what multiples were paid?
What were Lonza Chi’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?